Friday, 16 October 2026European Markets

BPOST Stock 13.5% Up On Monday

Loading stream...

(VIANEWS) - The Market ended the session with BPOST (BPOST.BR) rising 13.5% to €5.13 on Monday, after four consecutive sessions in a row of losses. BEL 20 fell 1.49% to €3,580.79, after two sequential sessions in a row of losses, on what was an all-around negative trend exchanging session today.

About BPOST

bpost NV/SA, together with its subsidiaries, provides mail and parcel services to individuals, businesses, and public institutions in Belgium, rest of Europe, the United States, and internationally. It operates through Belgium, E-Logistics Eurasia, E-Logistics North America, and Corporate segments. The company offers collection, transport, sorting, and distribution of addressed and non-addressed mail, printed documents, newspapers, periodicals, and parcels, as well as banking and financial products, e-commerce logistics, express delivery, proximity and convenience, document management, and related services. It also provides transactional mails, advertising mails, press, domestic and international parcels, logistic solutions, and cross-border products, as well as value-added services. The company was incorporated in 1830 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, BPOST has a trailing twelve months EPS of €0.96.

PE Ratio

BPOST has a trailing twelve months price to earnings ratio of 5.34. Meaning, the purchaser of the share is investing €5.34 for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BPOST's stock is considered to be overbought (>=80).

Volume

Today's last reported volume for BPOST is 864486 which is 300.15% above its average volume of 216038.

Volatility

BPOST's last week, last month's, and last quarter's current intraday variation average was a negative 1.11%, a positive 0.11%, and a positive 1.25%.

BPOST's highest amplitude of average volatility was 1.11% (last week), 1.25% (last month), and 1.25% (last quarter).

More news about BPOST (BPOST.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com